Primary: Vertically-integrated antibiotic production at Kundl with circular byproducts Kundl uses lactose (milk sugar) from regional cheese production as alternative sugar source for penicillin production, minimizing transport CO2 and promoting local circularity. Fungal mycelium byproducts from penicillin production are converted to Biosol bio-fertilizer (since 1981), distributed worldwide. Fourth-stage wastewater treatment implemented in 2023 to eliminate organic pollutants and APIs.
▾ expand
Zero water quality impact and zero waste to landfill by 2030 Sandoz set targets: PEC/PNEC ratio <1 for manufacturing sites and API supplier sites in scope by 2030; zero waste to landfill by 2030; all antibiotic production sites to obtain BSI AMR certification by 2030.
▾ expand
Primary: Product and packaging design-to-sustainable-value Sandoz introduced a 'Design-to-Sustainable-Value' workstream in 2024 to identify products with materials and emissions reduction opportunities. As part of Product Carbon Footprint analysis, identified products where packaging drives significant lifecycle emissions and proactively investigating ways to improve. Focus on circular economy opportunities in product design and manufacturing processes.
▾ expand
SBTi commitment letter submitted; net-zero by 2050 In January 2024, Sandoz submitted a Commitment Letter to the Science Based Targets initiative (SBTi) confirming intent to set near-term science-based carbon emissions reduction targets aligned with 1.5°C. Committed to net-zero emissions by 2050. Targets to be submitted to SBTi for validation by January 2026, with interim targets for 2030 and 2035.
▾ expand
Acquisition of Cimerli (biosimilar ranibizumab) On March 1, 2024, Sandoz closed acquisition of US Cimerli business from Coherus BioSciences for USD 170 million upfront + USD 18 million purchase price adjustment. Goodwill of USD 148 million recognized. Contributed USD 115 million net sales since acquisition.
▾ expand
China business divestment and Aspen portfolio swap On April 30, 2024, Sandoz closed swap of Sandoz China legal entity with Aspen Global Inc.'s surgical anesthesia portfolio plus cash. Realized pre-tax gain on divestment of USD 36 million.
▾ expand
Reports alignment with SDGs 3, 5, 6, 8, 10, 12, 13, 16 Sandoz aligns ESG pillars with UN SDGs: Driving Impact and Access (SDG 3, 8); Championing Sustainability (SDG 6, 12, 13); Empowering People (SDG 5, 10); Governing with Integrity (SDG 16).
▾ expand
Scope 3 categorization expanded with 4 new categories The Scope 3 categorization was updated in 2024 by adding 4 new categories (employee commuting, downstream transportation, processing of sold products, end-of-life treatment of sold products) that were not included in 2023 disclosure. 4 categories assessed as not material.
▾ expand
Sandoz Rewards Commitments Targets: All employees covered by annual pay equity studies by end of 2025 (achieved one year ahead); all employees covered by annual living wage studies by end of 2025; external/internal pay transparency by end 2027; removal of historical salary in offers by end 2025. Long-term goal: gender balance (45-55%) in senior leadership by 2030.
▾ expand
Health & Safety targets <0.32 LTIR and <0.55 TRCR by 2025 Lost time injury and illness rate <0.32 and total recordable case rate <0.55 (per 200,000 hours worked) by end of 2025 for Sandoz employees and third-party personnel.
▾ expand
see 5 more events →